Phase 2 N=31 Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Leukemia
Primary: Number of Patients With Complete Remission at One Year — 12; 13 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=52 A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Advanced Malignancies
Primary: Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 4; 4; 5; 5 Participants
Phase 2 N=200 Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
Atopic Dermatitis
Primary: Investigator's Global Assessment (IGA) — 12; 18; 87; 77 Participants
Phase 2 N=57 Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
Metastatic Non-small Cell Lung Cancer · NSCLC
Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 23; 33; 13; 19 Participants
Phase 2 N=20 Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
Myeloid Hematologic Malignancy · Lymphoid Hematologic Malignancy
Primary: Number of Patients Absence of Grade II-IV aGVHD or Chronic GVHD Diagnostic Features — 13; 5 Participants
Phase 2 N=34 A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
Lewy Body Disease · Parkinson Disease
Primary: Percent Change From Baseline in Cerebrospinal Fluid (CSF) Cyclic Guanosine Monophosphate (cGMP) at Week 9 — 230.412; 250.434; 186.869; 362.519 Percent Change in CSF…
Phase 2 N=34 TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
Neurogenic Orthostatic Hypotension · Multiple System Atrophy (MSA) With Orthostatic Hypotension · Pure Autonomic Failure
Primary: Part A: Change From Time-matched Placebo in Seated Systolic Blood Pressure (SBP) — 0.2; -1.8; -3.4; -2.9 millimeter of mercury (mmHg)
Phase 2 N=17 Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy
Muscular Dystrophy, Duchenne
Primary: Change From Baseline to Week 12 in the Lower Leg Composite of the MRI T2 Relaxation Time (LLC5-T2) - Part B — 2.04; 1.26; 0.34; 0.35 msec
Phase 2 N=79 Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke
Stroke · Stroke, Acute · Brain Injury, Acute
Primary: Shift in Modified Rankin Scale (mRS) — 1; 1 score on a scale — p=0.71
Phase 2 N=76 Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Stage I Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Percentage of Patients Achieving sCR — 76 percentage of participants
Phase 2 N=192 Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty
Hip Arthropathy
Primary: Daily Opioid Consumption — 29.3; 30.8; 49.6; 51.8 milligram — p=0.69
Phase 2 N=89 An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
Malignant Pleural Mesothelioma
Primary: Number of Participants With Progression Free Survival (PFS) Responders and Non-responders at Month 6 — 26; 51 Participants
Phase 2 N=28 Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Advanced Bile Duct Carcinoma · Advanced Gallbladder Carcinoma · Refractory Bile Duct Carcinoma
Primary: Progression-free Survival (PFS) — 37.0 percentage of participants
Phase 2 N=45 Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
Coronavirus Infection · Covid-19 · SARS-CoV-2
Primary: Proportion of Patients With Recovery — 29; 15 Participants — p=1
Phase 2 N=25 A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia
Primary: Percentage of Participants Attaining a Complete Response at Any Visit From Week 6 to Week 12 — 20.0; 40.0 percentage of participants